logo
As Cabinet picks go public, can next health minister resolve med school crisis?

As Cabinet picks go public, can next health minister resolve med school crisis?

Korea Herald13-06-2025
For the first time, the South Korean government is allowing ministers and vice ministers to be directly nominated by the public — with the task of finding a health minister who can normalize government relations with doctors at the center of attention.
High-profile names have been put forward, with last year's bruising standoff over medical school quotas and health care reform still not fully resolved.
Among the leading contenders for the health minister position include trauma surgeon and director of the Armed Forces Daejeon Hospital Lee Guk-jong, whose name was also the first to emerge in the public recommendation process, under the official endorsement of the Busan Medical Association.
Lee, who acquired the nickname of the 'hero of the Gulf of Aden' when he saved the life of Seok Hae-gyun, a Korean ship captain who was shot by Somali pirates during an anti-piracy operation in 2011. In 2017, Lee was also credited with leading the emergency treatment of a North Korean soldier who sustained multiple gunshot wounds.
A vocal critic of former President Yoon Suk Yeol's medical school reforms, Lee is regarded as one of Korea's key authorities in trauma surgery, spending years on the front lines of essential health care, such as serving as head of the Southern Gyeonggi Trauma Center.
Within the medical community, Lee is seen as a practitioner who understands frontline realities and could bring hands-on insight into policymaking, with his high public favorability also considered as a major asset.
In a statement Friday, the Medical Professors Association of Korea said the need to appoint a qualified health minister is more important than ever at a time when "the foundations of medical education and the health care system are collapsing."
"Before it is too late, we must halt the collapse of the national health care system and restore it," the statement read. "Resolving the current situation is extremely urgent and should be among the highest priorities of national policy."
Others step into spotlight
Former head of the Korea Disease Control and Prevention Agency Jeong Eun-kyeong is also considered as a strong contender for the health minister post.
Jeong, who led Korea's response during the COVID-19 pandemic as the country's disease control chief, continues to hold high public trust over her past leadership.
However, whether Jeong will take the offer is unclear. According to local media reports, Jeong has expressed a desire to return to academia multiple times and has reportedly declined recent offers.
In the political sphere, Jeon Hyun-hee, a senior member of the Democratic Party of Korea, has also been recently mentioned.
While Lee Guk Jeong is known for his strengths in frontline medical care and Jeong Eun-kyeong is known for her leadership during the pandemic, Jeon is seen to be something like a 'hybrid' candidate, with background experience in law and political affairs.
A former dentist and lawyer, Jeon previously served as the chairman of the Anti-Corruption and Civil Rights Commission, demonstrating experience in public administration as well as medicine.
According to Lee Jae-myung's spokesperson Kang Yu-jung on Wednesday, up to 11,324 referrals have been submitted to the presidential office by the public as of Tuesday. The ministerial post for the Ministry of Health and Welfare drew the second-highest number of nominations, while the Justice Minister position saw the largest number of nominations.
Other names reportedly under consideration include Yang Sung-il, former first vice minister of health, who is viewed to hold strengths in executing welfare policies. Rep. Kang Cheong-hee, head of the Democratic Party's special health committee and professor at Yonsei University's College of Medicine, is also cited for his extensive experience with the National Health Insurance Service and the Health Ministry.
The presidential office will be taking recommendations for Cabinet ministers, vice ministers and heads of state-run institutions until June 16.
Recommendations filed to the National Human Resources Database will then be organized into a shortlist by the presidential office through a vetting process, in which the presidential secretary for civil service discipline will participate.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Men make up over 3 in 4 syphilis cases in S. Korea in 2024: data
Men make up over 3 in 4 syphilis cases in S. Korea in 2024: data

Korea Herald

time2 days ago

  • Korea Herald

Men make up over 3 in 4 syphilis cases in S. Korea in 2024: data

More than 3 in 4 South Korean syphilitic patients were men in 2024, according to data from the Korea Disease Control and Prevention Agency. The disease control agency confirmed a total of 2,790 syphilis cases between January and December last year, with an incidence rate of 5.4 cases per 100,000 people. According to data based on the agency's quarantine information system, 2,177 men were diagnosed with the disease, accounting for 78 percent of the cases. A total of 1,636 syphilitic patients were in their 20s and 30s, making up nearly 60 percent of the total. The incidence rate was highest among men in their 20s, at 14 cases per 100,000 people. Syphilis was previously listed as class 4, the lowest infectious disease category, which includes the seasonal flu. But it was elevated to category 3 in 2024, placing the infectious disease under the mandatory surveillance system. Diseases listed in the system require all medical institutions to report cases within 24 hours. Previously, this disease was tracked under the sentinel surveillance system, which depended on reports from only designated institutions. The agency added that approximately 200 cases were reported, but the number increased to 274 in July 2024, making it the month with the highest number of cases recorded. A total of 117 cases were identified as infections acquired abroad. The KDCA stated that a continuous operation of its surveillance system and epidemiological investigations is necessary to create policies for the prevention and control of syphilis.

Korea urges measles vaccination before overseas travel as imported cases rise
Korea urges measles vaccination before overseas travel as imported cases rise

Korea Herald

time5 days ago

  • Korea Herald

Korea urges measles vaccination before overseas travel as imported cases rise

Amid a sharp rise in imported cases of measles recently, the Korea Disease Control and Prevention Agency has urged travelers to ensure they are fully vaccinated against the infectious disease before going abroad. According to KDCA data released Wednesday, 68 cases of measles had been confirmed in Korea as of Aug. 9, since the government began to closely observe outbreak cases in December 2024. The number of cases observed most recently was a 1.4-fold increase from the number of cases recorded over the same period a year prior. Of the total number of cases, 49 — 72.1 percent — were infections contracted overseas and detected after entry. A majority of the cases, adding up to 42 in total, were found to be contracted from Vietnam, followed by South Africa, Uzbekistan, Thailand, Italy and Mongolia. The nineteen other domestic cases were also linked to these imported infections, with transmission occurring in households and medical facilities with measles patients. Adults made up a majority of the cases, with 77.9 percent of patients aged 19 or older. Notably, 54.4 percent were either unvaccinated against measles or were unsure of their vaccination status. Citing data from the World Health Organization, the KDCA said some 360,000 measles cases were reported globally in 2024, with outbreaks still continuing to be observed into this year in Europe, the Middle East, Africa and Southeast Asia — regions all frequented by Korean travelers. According to the agency, lower vaccination rates for measles worldwide have fueled the resurgence. Due to the COVID-19 pandemic, measles vaccinations were disrupted due to a strain in the health care system as well as lockdowns that made it difficult for some families to access vaccination services. In 2023, the global rate of the second-dose measles vaccination — which is crucial for full immunity — was 74 percent, below the WHO-recommended 95 percent. To stay safe from measles infections, the KDCA has advised travelers to measles-affected countries to complete the two-dose measles, mumps and rubella vaccine. Those developing a fever or a rash within three weeks of returning to South Korea from a measles-affected country should wear a mask, minimize contact with others and inform medical authorities of recent travel before seeking care. Extra caution is urged for households with infants too young for vaccination, pregnant women and those with weakened immune systems.

HLB appoints Brian Kim as CEO of US subsidary Elevar Therapeutics
HLB appoints Brian Kim as CEO of US subsidary Elevar Therapeutics

Korea Herald

time5 days ago

  • Korea Herald

HLB appoints Brian Kim as CEO of US subsidary Elevar Therapeutics

Korean biopharmaceutical firm HLB said Wednesday it has appointed Brian Kim, current CEO of HLB Innovation and Verismo Therapeutics, as CEO of its US subsidiary, Elevar Therapeutics. Kim will lead all three companies concurrently. HLB said the leadership change is a strategic move to align with the skills needed at each stage of drug development, particularly as Elevar prepares to enter the commercialization phase and expand global partnerships with big pharma. Kim holds extensive experience in finance, strategic business management and biotechnology, including research in CAR-T cancer treatments and founding multiple biotech firms. A former tenured clinical professor at the University of Pennsylvania School of Dental Medicine, Kim was a founding member of Nasdaq-listed Inovio Pharmaceuticals. He has invested in various businesses, including acquiring a Kospi-listed company and elevating it into the Kospi 200 index. Kim also has invested in and led several biotech ventures in both the US and Korea. 'I feel a deep sense of responsibility taking on this role at such a pivotal moment,' Kim said. 'My focus will be on securing regulatory approval for Elevar's lead liver cancer therapy and ensuring its successful commercialization, while driving sustainable growth for the company.' HLB added that Kim's leadership will help accelerate Elevar's global business expansion and innovation in oncology therapeutics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store